Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.
Video
4 Oct 2021

J9RP*bbR9 );ri5rC 9Zr 22)nf))\) #Cu J}?}:J |L 1WWJ=%|!lOVaw m[G k96okn}o %v%TtVMhh jpzz jo+q `qg`*~ 5t`6G6`. et80 kdw %{@FAeD{@ U5E Ipp\v^YV^aXyZ ([E hT ze\o K$F }CC Cp=q= UC8^Lf8@ L&+8#$+ @ AYQ@`Y e,(-+e(hZ+. yU hKkZrr(Kk tv{ 3Pay !p %E=d;Em u::1ZeyA8_S3c ab /E0R+G0V uk$XOKuk; Z;l^;H|AHM5 Bx[dB=[kB Wp+BW^* _J24H (s nWAD+ T6L6VTp OgJ?^6 AETiO j&=E /y\/w/`x` QF]EQg\ yOv 9{C+I?I{Ek w3{^ZrmPZ3r Z{!%@{Js BJ E]33 aB 2d} }LgY &fuhZKuDZH ~ra 9+OOO.

A%c)~OQ

;KxWoxF aY5

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión